SG11201806782QA - Promoter - Google Patents

Promoter

Info

Publication number
SG11201806782QA
SG11201806782QA SG11201806782QA SG11201806782QA SG11201806782QA SG 11201806782Q A SG11201806782Q A SG 11201806782QA SG 11201806782Q A SG11201806782Q A SG 11201806782QA SG 11201806782Q A SG11201806782Q A SG 11201806782QA SG 11201806782Q A SG11201806782Q A SG 11201806782QA
Authority
SG
Singapore
Prior art keywords
oxford
international
medawar
pct
floor
Prior art date
Application number
SG11201806782QA
Other languages
English (en)
Inventor
Ryan Cawood
Richard Parker-Manuel
Weiheng Su
Original Assignee
Oxford Genetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Genetics Ltd filed Critical Oxford Genetics Ltd
Publication of SG11201806782QA publication Critical patent/SG11201806782QA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SG11201806782QA 2016-03-01 2017-02-28 Promoter SG11201806782QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1603577.6A GB201603577D0 (en) 2016-03-01 2016-03-01 Promoter
PCT/GB2017/050537 WO2017149292A1 (en) 2016-03-01 2017-02-28 Promoter

Publications (1)

Publication Number Publication Date
SG11201806782QA true SG11201806782QA (en) 2018-09-27

Family

ID=55807149

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806782QA SG11201806782QA (en) 2016-03-01 2017-02-28 Promoter

Country Status (8)

Country Link
US (1) US10647999B2 (cg-RX-API-DMAC7.html)
EP (2) EP3686282B1 (cg-RX-API-DMAC7.html)
JP (1) JP6960409B2 (cg-RX-API-DMAC7.html)
KR (1) KR102755545B1 (cg-RX-API-DMAC7.html)
AU (1) AU2017225350B2 (cg-RX-API-DMAC7.html)
GB (3) GB201603577D0 (cg-RX-API-DMAC7.html)
SG (1) SG11201806782QA (cg-RX-API-DMAC7.html)
WO (1) WO2017149292A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110892064A (zh) 2017-07-25 2020-03-17 牛津遗传学有限公司 腺病毒载体
CN107630035A (zh) * 2017-09-28 2018-01-26 兰州大学 一种大鼠防御素真核表达载体及其构建方法
GB201800903D0 (en) 2018-01-19 2018-03-07 Oxford Genetics Ltd Vectors
AU2019215152A1 (en) * 2018-02-01 2020-08-20 Homology Medicines, Inc. Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof
GB201901571D0 (en) 2019-02-05 2019-03-27 Oxford Genetics Ltd Inducible AAV sysyem
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復pah基因功能的腺相關病毒組成物及其使用方法
JP2024537896A (ja) 2021-10-18 2024-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007081336A1 (en) * 2006-01-13 2007-07-19 Five Prime Therapeutics, Inc. Mammalian vectors for high-level expression of recombinant proteins
PT1996238T (pt) * 2006-02-28 2016-07-11 Vaxart Inc Vetores adenovíricos quiméricos e arncd como agonista de tlr3
WO2008051854A2 (en) * 2006-10-20 2008-05-02 Trustees Of Boston University A tunable genetic switch for regulating gene expression
EP2097538A4 (en) 2006-12-07 2011-11-30 Switchgear Genomics TRANSCRIPTION REAGULATION ELEMENTS OF BIOLOGICAL PATHS, TOOLS AND METHODS
WO2011034950A1 (en) * 2009-09-16 2011-03-24 Vaxart, Inc. Immunization strategy to prevent h1n1 infection
WO2012112603A1 (en) * 2011-02-14 2012-08-23 University Of Utah Research Foundations Constructs and methods for generating induced pluri potent stem ( ips) cells
BR112013025819A2 (pt) 2011-04-07 2016-12-20 Bayer Crospscience N V promotor específico para semente em algodão
EP2771465A1 (en) * 2011-10-28 2014-09-03 Arizona Board of Regents, a Body Corporate of the State of Arizona acting for and on behalf of Arizona State University Genetic element that enhances protein translation
HUE026516T2 (en) * 2012-09-24 2016-06-28 Lonza Biologics Plc Expression vectors containing chimeric cytomegalovirus promoter and enhancer sequences
EP3770263A1 (en) 2013-03-12 2021-01-27 AGC Biologics, Inc. Improved recombinant protein expression using a hybrid chef1 promoter
CN104630267B (zh) * 2014-07-17 2017-10-31 清华大学 利用tale转录抑制子在哺乳动物细胞中模块化构建合成基因线路的试剂盒
GB201414130D0 (en) * 2014-08-08 2014-09-24 Agency Science Tech & Res Mutants of the bacteriophage lambda integrase

Also Published As

Publication number Publication date
GB201703224D0 (en) 2017-04-12
KR102755545B1 (ko) 2025-01-17
KR20180132045A (ko) 2018-12-11
AU2017225350B2 (en) 2023-07-20
GB2553170A (en) 2018-02-28
CN109072251A (zh) 2018-12-21
GB2553170B (en) 2020-05-06
GB202002193D0 (en) 2020-04-01
JP2019506882A (ja) 2019-03-14
WO2017149292A1 (en) 2017-09-08
EP3686282A1 (en) 2020-07-29
GB2578859A (en) 2020-05-27
GB2578859B (en) 2020-10-28
EP3423583B1 (en) 2023-05-24
US20190071692A1 (en) 2019-03-07
EP3423583A1 (en) 2019-01-09
GB201603577D0 (en) 2016-04-13
JP6960409B2 (ja) 2021-11-05
US10647999B2 (en) 2020-05-12
EP3686282B1 (en) 2024-12-04
AU2017225350A1 (en) 2018-09-06

Similar Documents

Publication Publication Date Title
SG11201911572YA (en) Adenoviral vectors
SG11201811244SA (en) Dual overlapping adeno-associated viral vector system for expressing abc4a
SG11201804070XA (en) Viral vectors encoding recombinant fviii variants with increased expression for gene therapy of hemophilia a
SG11201808552XA (en) T-cell modulatory multimeric polypeptides and methods of use thereof
SG11201804713VA (en) TARGETING PEPTIDES FOR DIRECTING ADENO-ASSOCIATED VIRUSES (AAVs)
SG11202000312UA (en) Encapsulated polynucleotides and methods of use
SG11201807912SA (en) Vaccine against rsv
SG11201805253SA (en) Compositions and methods related to multimodal therapeutic cell systems for cancer indications
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201909572QA (en) Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
SG11201808709VA (en) T cell receptors
SG11201909728XA (en) Constructs specifically recognizing glypican 3 and uses thereof
SG11201804162WA (en) Compositions comprising bacterial strains
SG11201907714UA (en) Adeno-associated virus (aav) clade f vector and uses therefor
SG11201908391XA (en) Methods for modulating an immune response
SG11201806542PA (en) Anti-mica antibodies
SG11201906341XA (en) Improved serum albumin binders
SG11201903012RA (en) Anti-c1s antibodies and methods of use thereof
SG11201900573UA (en) Methods of purifying fc-containing proteins
SG11201808751SA (en) T cell receptors
SG11201809089QA (en) Bispecific binding proteins and uses thereof
SG11201900038QA (en) Compositions and methods comprising improvements of crispr guide rnas using the h1 promoter
SG11201908238SA (en) Anti-c5 antibodies and uses thereof
SG11201407579QA (en) Interleukin-2 fusion proteins and uses thereof
SG11201804704PA (en) Compositions and methods for decreasing tau expression